Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI boosts Radiologists' accuracy in stomach cancer staging

NCT ID NCT07651644

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an artificial intelligence (AI) tool can help radiologists more accurately determine the stage of stomach cancer from CT scans. Fifty-four radiologists will review 60 scans each, first without AI help and then with AI assistance, to see if the AI improves their accuracy. The goal is to improve cancer diagnosis and guide better treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (Imaging Data) 1. Contrast-enhanced CT (CE-CT) images of gastric cancer patients from the Liaoning Cancer Hospital; 2. Patients with a definitive postoperative pathological diagnosis of gastric cancer and a clear T-stage classification (T1-T4, including T4a and T4b); 3. Imaging data must be complete and of sufficient quality to meet diagnostic and analytical requirements, with no significant artefacts or missing key data; 4. Complete clinical and pathological information must be available to establish a diagnostic gold standard for comparison. Physician Inclusion Criteria (Image Readers) 1. Radiologists holding a valid medical licence; 2. From the radiology department of a Grade A tertiary hospital or a non-Grade A tertiary hospital; 3. Classified as senior or junior physicians based on clinical experience; 4. Voluntarily participating in this study and completing both the non-AI-assisted and AI-assisted image interpretation tasks. Case Exclusion Criteria 1. Severe missing imaging data or quality failing to meet analysis requirements (e.g., severe motion artefacts); 2. Lack of clear postoperative pathological T-staging results; 3. Cases not involving gastric cancer or with incomplete pathological information; 4. Cases of duplicate enrolment or inconsistent data recording. Physician Exclusion Criteria 1. Those unable to complete all image review tasks or demonstrating severe non-compliance; 2. Those who withdraw during the study period and are unable to provide complete data for both phases of image review; 3. Those who fail to complete the AI-assisted and non-AI-assisted interpretation processes as specified. Withdrawal Criteria 1. Physicians who voluntarily withdraw from the study for personal reasons (e.g., time, health or work commitments); 2. Physicians who fail to complete the required image review tasks or have data missing in excess of the specified threshold; 3. Cases where critical data errors are identified during subsequent verification or where pathological results cannot be traced; Data found during the study to be non-compliant with ethical or quality control requirements must be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer (diagnosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute)

    RECRUITING

    Shenyang, Liaoning, 110024, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.